Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659891 | 0.87 | GAA (0.47) | L3MBTL1POLBSLC6A3CYP26A1CNR2 | |
| SCHEMBL4659918 | 0.79 | PPARA (0.38) | POLBCNR2CNR1KMT2A | |
| SCHEMBL4659864 | 0.78 | HDAC3 (0.41) | L3MBTL1GAACYP1A2CNR1MEN1 | |
| SCHEMBL4661240 | 0.78 | HTR1A (0.39) | L3MBTL1POLBGAACYP1A2CNR1 | |
| SCHEMBL4661128 | 0.77 | HDAC3 (0.48) | L3MBTL1POLBGAACYP1A2CNR1 | |
| SCHEMBL4659908 | 0.75 | HDAC8 (0.45) | L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL4661257 | 0.74 | MMP12 (0.40) | L3MBTL1POLBGAACYP1A2CNR1 | |
| SCHEMBL4659861 | 0.74 | HDAC3 (0.38) | L3MBTL1POLBGAACYP1A2CNR1 | |
| SCHEMBL4662610 | 0.73 | MME (0.35) | L3MBTL1POLBGAACYP1A2CNR1 | |
| SCHEMBL4661171 | 0.73 | MME (0.37) | L3MBTL1POLBGAACYP1A2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627866-B1 | CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-7109242-B2 | Carboxylic compound and medicine comprising the same | KOWA COMPANY, LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1627866-A1 | CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20050009909-A1 | Carboxylic compound and medicine comprising the same | KOWA COMPANY, LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009909-A1 | Carboxylic compound and medicine comprising the same | CPT1A, GPR119, PNLIP | L3MBTL1 2080/4885POLB 4352/4885SLC6A3 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.